
CAS 1420367-28-7
:Formule :C21H17F5N4O3
InChI :InChI=1S/C21H17F5N4O3/c1-29-5-2-6-30-18(29)9-17(28-20(30)31)32-11-12-7-14(22)19(15(23)8-12)33-13-3-4-16(27-10-13)21(24,25)26/h3-4,7-10H,2,5-6,11H2,1H3
Code InChI :QJIGPJZJKXZSNF-UHFFFAOYSA-N
SMILES :CN1CCCN2C1=CC(=NC2=O)OCC3=CC(=C(C(=C3)F)OC4=CN=C(C=C4)C(F)(F)F)F
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
5 produits trouvés.
Lp-PLA2-IN-1
CAS :Lp-PLA2-IN-1 suppresses Lp-PLA2, aiding in treating atherosclerosis and Alzheimer's.Formule :C21H17F5N4O3Degré de pureté :99.60%Couleur et forme :White SolidMasse moléculaire :468.38Lp-PLA2-IN-1
CAS :8-((3,5-Difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-1-methyl-1,2,3,4-tetrahydro-6H-pyrimido[1,6-a]pyrimidin-6-oneFormule :C21H17F5N4O3Degré de pureté :99%Masse moléculaire :468.38Lp-PLA2 -IN-1
CAS :Lp-PLA2-IN-1 is a small molecule inhibitor, which is derived from chemical synthesis, designed to specifically inhibit the activity of lipoprotein-associated phospholipase A2 (Lp-PLA2). This enzyme is involved in the hydrolysis of oxidized phospholipids on low-density lipoproteins (LDL), leading to the production of pro-inflammatory mediators. The mode of action involves the selective binding to the active site of Lp-PLA2, thus preventing the enzyme from catalyzing its reaction and subsequently reducing the formation of pro-inflammatory lysophosphatidylcholine and oxidized free fatty acids.Formule :C21H17F5N4O3Degré de pureté :Min. 95%Masse moléculaire :468.38 g/mol




